Evidence map›Paper›PMID 33278332›Full record

Trial reportClinical and translational science2021

Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery.

Kate Mostoller, Rebecca Wrishko, Lata Maganti, W Joseph Herring, Mariëlle van Zutphen-van Geffen

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03346070 (A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03346070 phase4completednot on this map

A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2018 to 2019Enrolled207ConditionsNeuromuscular BlockadeArmsSugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kate MostollerDepartment of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Rebecca WrishkoDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Lata MagantiDepartment of Biostatistics, Merck & Co., Inc., Kenilworth, New Jersey, USA.
W Joseph HerringDepartment of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Mariëlle van Zutphen-van GeffenCertara Strategic Consulting, Oss, The Netherlands.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USABS Consulting (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This analysis of a published study (NCT03346070) evaluated the pharmacokinetics (PKs) of sugammadex dosed by actual body weight (ABW) or ideal body weight (IBW) for reversal of moderate or deep neuromuscular block (M-NMB or D-NMB) in adults with morbid obesity. Adults with body mass index ≥ 40 kg/m

Indexed as

AdultBody Mass IndexDose-Response Relationship, DrugDrug Dosage CalculationsFemaleHumansIdeal Body WeightMaleMiddle AgedModels, BiologicalNeuromuscular BlockadeNeuromuscular Nondepolarizing AgentsObesity, MorbidRocuroniumSugammadexVecuronium BromideNeuromuscular Nondepolarizing AgentsRocuroniumSugammadexVecuronium Bromide

Identifiers

PMID33278332
PMCPMC7993252
OpenAlexW3113368618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.